Last reviewed · How we verify

Blocked

Vanderbilt University · FDA-approved active Small molecule ✓ Verified May 2026

Blocked is a Small molecule drug developed by Vanderbilt University. It is currently FDA-approved. Also known as: Trimethaphan.

The iLUX Treatment System is being studied for the treatment of Meibomian Gland Dysfunction and Chronic Rhinosinusitis. The system is also being used in experiments involving auditory and visual perception in healthy volunteers.

At a glance

Generic nameBlocked
Also known asTrimethaphan
SponsorVanderbilt University
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Blocked

What is Blocked?

Blocked is a Small molecule drug developed by Vanderbilt University.

Who makes Blocked?

Blocked is developed and marketed by Vanderbilt University (see full Vanderbilt University pipeline at /company/vanderbilt-university).

Is Blocked also known as anything else?

Blocked is also known as Trimethaphan.

What development phase is Blocked in?

Blocked is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing